Novartis, Incyte will take Jakafi into 2nd trial for COVID-19 patients on ventilators

Novartis and Incyte announced their first Jakafi study in COVID-19 back in April. (Novartis)

Novartis and Incyte have already pitted their blockbuster JAK inhibitor Jakafi against COVID-19 as a possible treatment for a severe respiratory immune reaction. Now, seeing promise in another category of coronavirus-afflicted patients, the partners will take Jakafi into a second late-stage trial. 

The partners plan to test Jakafi in a second phase 3 trial for COVID-19 patients with acute respiratory distress syndrome (ARDS), the drugmaker announced alongside first-quarter earnings Tuesday.

The U.S. trial will evaluate Jakafi's safety and efficacy over standard of care in ARDS patients who've needed ventilators.

Incyte and partner Novartis announced in early April that they would roll Jakafi—also known as ruxolitinib—into a phase 3 study evaluating its ability to treat cytokine storm, an immune system overreaction that can cause severe respiratory complications. 

RELATED: Novartis, Incyte set to roll JAK inhibitor Jakafi into COVID-19 clinical trial

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.